Research article
Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
-
* Corresponding author: Howard Trachtman trachtma@lij.edu
BMC Nephrology 2010, 11:2 doi:10.1186/1471-2369-11-2
No comments have yet been made on this article.